Semaglutide vs Sitagliptin

PHASE4UnknownINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

October 26, 2022

Primary Completion Date

April 30, 2024

Study Completion Date

December 31, 2024

Conditions
Liver Transplant; ComplicationsDiabetes MellitusNASH - Nonalcoholic SteatohepatitisNAFLD
Interventions
DRUG

Semaglutide Treatment

"The participants will be provided with Semaglutide, titrated up to 14 mg. The starting dose of Semaglutide is 3 mg once daily. At week 4, the dose will be increased to 7 mg once daily. At week 8, the dose will be increased to 14 mg once daily and will be maintained at 14mg until End of Treatment (week 26). Throughout the 26 week treatment period, participants in this arm will also take one sitagliptin placebo tablet per day."

DRUG

Sitagliptin 100mg

"participants will take 100mg tablet of Sitagliptin once daily, along with a semaglutide placebo pill for the duration of the 26 week treatment period"

Trial Locations (1)

M5G 2N2

Toronto General Hospital, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novo Nordisk A/S

INDUSTRY

lead

University Health Network, Toronto

OTHER